Comparative, randomized, double-blind study of microneedling associated with drug delivery for rejuvenating the skin of the anterior thorax region

Estudo comparativo, randomizado e duplo-cego do microagulhamento associado ao drug delivery para rejuvenecimento da pele da região anterior do tórax

ABSTRACT

Introduction: Photodamaged skin of the anterior thorax region is characterized by flaccidity, wrinkles, hyperpigmentation, erythema, telangiectasia, and atrophy. Microneedling has been used for the transdermal drug delivery of active agents to the skin through microchannels.

Objective: To clinically evaluate the rejuvenation of the skin of the anterior thorax region resulting from the use of microneedling associated with drug delivery.

Methods: Double-blind randomized, placebo-controlled study conducted with 22 women who underwent three microneedling sessions followed by the topical application of a test product containing hyaluronic acid and other active principles or placebo. The evaluation was performed through photographic comparison carried out by a dermatologist oblivious to the study and the application of self-assessment questionnaires to patients.

Results: Clinical evaluation showed improvement in the overall skin rejuvenation of the anterior thorax region in 100% of the patients. The statistical analysis showed a 28% improvement (p < 0.05) with use of the test product as compared to the placebo. The responses to the questionnaires demonstrated an improvement of 30% in the patients treated with microneedling and the test product.

Conclusions: The microneedling technique associated with the transdermal administration of drugs used for rejuvenation provides improved overall appearance of the skin of the anterior thorax region, with a high degree of tolerability and satisfaction.

Keywords: rejuvenation; collagen; administration; cutaneous

RESUMO

Introdução: A pele fotodanificada da região anterior do tórax caracteriza-se por flacidez, rugas, hiperpigmentação, eritema, telangiectasias e atrofia. O microagulhamento tem sido usado para a entrega transdérmica de agentes ativos na pele através de microcanais, denominada drug delivery.

Objetivo: Avaliação clínica do rejuvenescimento da pele da região anterior do tórax usando microagulhamento associado ao drug delivery.

Métodos: Estudo duplo-cego randomizado, placebo controlado, realizado com 22 mulheres submetidas a três sessões de microagulhamento seguidas da aplicação tópica de um produto teste contendo ácido hialurônico e outros ativos ou placebo. A avaliação, por comparação fotográfica, foi realizada por dermatologista alheio ao estudo e pela aplicação aos pacientes de questionários de autoavaliação.

Resultados: A avaliação clínica demonstrou melhora no rejuvenescimento global da pele da região anterior do tórax em 100% das pacientes. Sua análise estatística mostrou melhoria de 28% (p < 0.05), com o uso do produto teste em comparação ao do placebo. A aplicação dos questionários às pacientes demonstrou melhora de 30% naqueles tratadas com microagulhamento e produto teste.

Conclusões: A técnica de microagulhamento associada à administração transdérmica de fármacos utilizada para rejuvenescimento proporciona melhora da aparência global da pele da região anterior do tórax com elevada tolerabilidade e satisfação.

Palavras-chave: rejuvenescimento; colágeno; administração cutânea

DOI: http://dx.doi.org/10.5935/scd1984-8773.201573661

The present study was conducted at the Dermatology Departments of the Santa Casa de Misericórdia de Porto Alegre - Porto Alegre (RS), Brazil.

Financial support: All topical products used in the study were supplied by Farmatec – Farmácia de Manipulação Ltda., Porto Alegre (RS), Brazil.

Conflict of interests: None
INTRODUCTION

Skin aging results from the action of both individual genetically determined factors and external factors, such as smoking, pollution, chronic exposure to sunlight, and other adjuvant factors, such as stress, use of drugs, the impact of cutaneous and systemic diseases, in addition to hormonal factors.1-3

The anterior region of the thorax is an area that shows the extent of skin aging, since it is usually exposed to sunlight and often not treated at all.4,5 There are few published studies on the treatment of the skin in this region. The aging of the anterior thorax region manifests as muscle and skin sagging, brownish irregular diffuse pigmentation, xerosis, superficial and deep rhytids, epheides, poikiloderma,6,7 hypomelanosynthesis and pre-neoplastic and neoplastic lesions.8-9 Moreover, it is known that the healing process becomes impaired, causing tissue repair of spontaneous injuries or those caused by surgical procedures in this region to happen more slowly10,11 due to the reduced number of adnexa.

In order to correct these alterations, diverse procedures can be employed, namely chemical peels, injectable hyaluronic acid, botulinum toxin, radio frequency, infrared radiation, intense pulsed light, photodynamic therapy and fractional ablative and non-ablative lasers.12,13 A promising technique known as microneedling is currently used in the successful treatment of facial cutaneous aging. Nevertheless, there is lack of studies describing the use of this technique for rejuvenating the skin of the anterior thorax region.14,15

Furthermore, microneedling can be associated with a procedure that allows the transdermal delivery of selected active principles (drug delivery), and can optimize the results sought. This technique uses the transport of drugs through the skin, with the advantage of being easily obtainable, non-invasive, safe, and effective. However, its clinical application is limited by the stratum corneum, which is the barrier of the main skin. Due to its hydrophobic characteristic and negative electrical charge, the transportation of hydrophilic and ionized molecules is a major challenge.

In this manner, the present study aims at evaluating the clinical efficacy and safety of a new and original approach to the treatment of the anterior surface of the chest area using microneedling associated with the drug delivery process.

METHODS

This is an original, prospective, multicenter, comparative, double-blind, randomized (by drawing lots), and placebo controlled study aimed at evaluating the clinical efficacy of a test product applied on the skin of the anterior chest region, in association with the microneedling procedure. There is an absence of similar publications. It was conducted at two research centers located within dermatologic private practices – one in Porto Alegre (RS, Brazil) and the other in Jundiaí (SP, Brazil) – in 2014.

Twenty-two women treated for rejuvenation of the anterior surface of the skin of the thorax were included (average age = 55, Fitzpatrick skin phototype 1 to IV16 and Glogau classification of aging 2 to 4.17 The exclusion criteria are listed in Chart 1.

The evaluation of the results of the treatment was carried out before (D0) and 30 days after the three monthly procedures (D90) of microneedling associated with the application of the test product or placebo (D0, D30, and D60), according to randomization by drawing lots. The study was conducted after the signing of the Free and Informed Term of Consent, and according to the ethical guidelines of the Helsinki Declaration.

The microneedling procedure was performed after the application of topical anesthetic cream and after the marking of the region (Figure 1).

The microneedling device used in the study was a roller (Dr. Roller®, Moohan Enterprise, South Korea) consisting of 192 micro needles made of surgical steel measuring 0.07 mm in thickness and 1.5 mm in length (registered at ANVISA/MS under the number 80669600001, and imported by the company MTO Importadora e Distribuidora Ltda., São Leopoldo (RS), Brazil). To perform the procedure, the device was positioned in one hand with minimum pressure at an angle of 45° on the area to be treated. Ten movements with passes in four directions

<table>
<thead>
<tr>
<th>CHART 1: Exclusion criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>Previous history of hypertrophic scars and/or keloid</td>
</tr>
<tr>
<td>- Diabetes</td>
</tr>
<tr>
<td>- Neuromuscular disease</td>
</tr>
<tr>
<td>- Bleeding disorder</td>
</tr>
<tr>
<td>- Collagen vascular disease</td>
</tr>
<tr>
<td>- Acute or chronic corticosteroid therapy</td>
</tr>
<tr>
<td>- Acute or chronic therapy with anticoagulant</td>
</tr>
<tr>
<td>- Presence of skin cancers</td>
</tr>
<tr>
<td>- Warts in the study area</td>
</tr>
<tr>
<td>- Solar keratosis in the study area</td>
</tr>
<tr>
<td>- Cutaneous infection</td>
</tr>
<tr>
<td>- Pregnancy</td>
</tr>
<tr>
<td>- Unrealistic expectations about the study</td>
</tr>
<tr>
<td>- Treatment in the anterior region of the thorax fewer than six months before the beginning of the study (carried out with ablative or non-ablative laser, deep peeling)</td>
</tr>
<tr>
<td>- Use of systemic isotretinoin fewer than three months prior to the beginning of the study</td>
</tr>
<tr>
<td>- Previous history of herpes in the treated area</td>
</tr>
<tr>
<td>- Previous history of allergy to anesthetics, such as lidocaine and/or tetracaine</td>
</tr>
</tbody>
</table>

FIGURE 1: Marking of the microneedling application area
(horizontal, vertical, diagonal right and left) were carried out, causing uniform micro bleeding points. Cleansing with gauze moistened with thermal water was carried out immediately after, with the test product or placebo being subsequently applied. This application was directed and performed by the technician responsible for the study at the research center. Three similar sessions were performed at monthly intervals (D0, D30, and D60).

The test product was a compounded formulation comprising: 2% Juvenate®; 0.5% PhytoCellTec Malus Domestic®; 2% Cell to Cell®; 5% Homeostatine®; 2.5% Hyaluronic Acid; 30 ml anhydrous fluid serum QS. The association of these substances of cosmetic use was used with the main purpose of increasing the duration of the opening of the pores, and stimulating the production of collagen and elastin, relying on anti-inflammatory action to avoid discomfort during the application.

After the first procedure (D0), the patients were instructed to carry out the application of the same product or placebo at home, gently massaging with the fingertips, until it was completely absorbed, once a day, at night, in the area being treated. The procedure should be repeated up until the following sessions and evaluations (D30, D60 and D90). Each volunteer used only one of the treatments up until the end of the study.

The following evaluations were performed: clinical efficacy (through photographic assessment of the overall skin rejuvenation in the anterior chest, comparing D0 with D90, performed by a dermatologist blinded to which patients had applied the test formulation or placebo); subjective evaluation through the application of patient questionnaires on the improvement of the following factors related to the rejuvenation of anterior chest region’s skin: wrinkles, texture, luminosity, smoothness, tone, firmness and overall appearance. Assessment was also performed through Visia® digital photography system (Canfield Imaging Systems, USA) in some patients. The safety assessment of the procedure and the product was based on the patient’s acceptance and tolerance as well as on the adverse effects observed.

Statistical analysis of the clinical efficacy

The results were expressed as mean ± standard error of the mean value (SEM) and statistically evaluated through the analysis of the Student t test. A significance limit of p <0.05 was used in all results. The data represent the mean ± SEM. *P<0.05 versus placebo within the same group.

RESULTS

The 22 patients treated completed the study. The duration of the follow-up was three months. The results obtained are described below.

The clinical efficacy assessment demonstrated a significant improvement in 100% of the treated patients. The statistical analysis suggested there was 28% of improvement in the overall skin rejuvenation of the anterior thorax (p <0.05) when the test product was used as compared to the placebo, after three months of treatment (Graph 1).

The patients’ self-assessment suggested an improvement of 30% in the patients treated with the combined use of microneedling and the test product, when considering the following variables: skin’s texture, smoothness and firmness.

Graph 1: Statistical evaluation demonstrating a 28% clinical improvement (p ≤ 0.05) in the general appearance of the anterior region of the thorax when treated with the test product as compared to the placebo

DISCUSSION

The skin has an excellent barrier property, protecting the body from physical and chemical agents, thus being able to restrict the transdermal access of a large number of drugs – even those with low molecular weight or lipophilic ones. The topical application of compounds has the potential to be a safe and ideal alternative route for administration into the tissue. The use of techniques that facilitate the permeation of active principles increases the potential of the latter for action. The combined use of microneedling and drug delivery proves to be essential for the positive clinical results obtained.

Microneedling has been described as a virtually painless, simple, and minimally invasive technique. The use of microneedling allows the creation of a means of transport accessible to macromolecules and other hydrophilic substances into the skin. Thus, microneedling is a fundamental tool for the product used in the study to act in the dermis through an essential and necessary amount for achieving the results effectively and quickly, with only three treatment sessions.

The technique promotes the disruption of the stratum corneum (this is microscopically proven through the visualization of channels and the increased transepidermal water loss – TEWL). As a consequence, there is increased permeation of the formulations’ hydrophilic molecules and macromolecules when it is applied once the microneedling’s perforations have
been performed.  

In this way, the length of the needles was long enough to pierce the more superficial layers of the epidermis and short enough not to excite the nerve endings in the skin, with good patient tolerability and acceptance. All patients in the present study continued the treatment up until its end.

There are few therapeutic resources described for a treatment aimed at a general rejuvenation of the skin of the anterior thorax region. According to Peterson et al., the main techniques described in the literature are: the use of injectable polylactic and hyaluronic acids, botulinum toxin, sclerotherapy, chemical peels, and more recently lasers and light-based therapies, such as intense pulsed light (IPL), photodynamic therapy (PDT), fractional ablative and non-ablative lasers. These are minimally invasive options for rejuvenating the skin of the anterior thorax region, which are well tolerated by patients and present a low incidence of side effects. However, the use of fractional ablative laser can increase recovery time, since the skin is thinner and has smaller concentrations of pilosebaceous units. Consequently, if not performed carefully, some of these procedures can cause local scarring and hyperpigmentation alterations. According to the results obtained in the present study, microneedling appears to be a safer and less invasive technique for the treatment of the anterior surface of the thorax than fractional ablative laser. As a result, the authors aimed at developing a new and original approach to the treatment of the skin of the anterior thorax region using the microneedling technique combined with drug-delivery.

The choice of the formulation’s components and characteristics of the drugs used in the drug delivery may influence the permeation and degree of skin irritation. The use of hyaluronic acid, for instance, has been indicated to increase the duration of pore opening. Controlled release systems can help to increase the depth reached by the active principles, such as liposomes, which increase the bioavailable concentration of the active principle crossing the stratum corneum, for enhanced bioavailability in the skin. The choice of the ideal vehicle for the formulation is also another determining factor for good performance. Fluid anhydrous serum is safe and effective, without causing burning or discomfort to the patient at the moment of application, and also has the advantage of forming a film on the skin, causing occlusion, which is of the utmost importance for significantly increasing the duration of the opening of pores and reducing the transepidermal water loss (TEWL).

The present study sought to use a topical product that facilitated the permeation in a safe manner and allowed for the association with rejuvenating active principles that were crucial for the positive results obtained with the combined treatment. The active principles used in the present study’s test formulation achieved the primary goal of a general rejuvenation of the skin of the anterior thorax region. The active principles used prevent the rupture of collagen fibers, have an anti-inflammatory action and inhibit metalloproteinases (MMPs), and activate the cutaneous cell metabolism. Furthermore, the set of active principles used – Cell to Cell®, Juvenile®, apple stem cells and Homeostatine® – lends synergy of action to the formulation, with an absence of signs of irritation or burning in the skin, even immediately after the procedure.

Applying the test formula at home after the procedure was key to improved healing, moisturizing, and lower TEWL, with better clinical responses.

During the study it was possible to observe significant changes in the progressive improvement of the treated area in the skin of the anterior thorax region (the differences in the
results of patients became evident from 60 days of treatment), in the alignment with the subjective and clinical evaluations, and in the statistical analysis, which showed a significant improvement of 28% when comparing the pre-treatment experimental time point with 90 days after.

This study has demonstrated that the use of formulations during and after the procedure not only enhances the outcome of the technique but also minimizes the potential for side effects, such as pigmentary alterations. With the statistical analysis, it was possible to prove correctness of the subjective data, with the significant improvement in patients treated with the test product as compared to the placebo.

The multicenter study used a standardized sample that presented the greatest possible similarity to the routine patient in a dermatologist’s practice. In addition, a cohesive sample is associated with the adequate comparative response of the data, therefore allowing the assertion that the data found are due to the efficiency of the active principles and not to idiosyncratic responses to the treatment. The microneedling technique is considered safe for any skin phototype (especially higher ones).

Our findings demonstrate the general clinical improvement in the rejuvenation of the skin of the anterior thorax region with microneedling techniques in association with drug-delivery. However, further studies are necessary to estimate the histological improvement with the application of the technique.

CONCLUSION

The microneedling technique is firmly established and safe, nevertheless in order to obtain an advanced degree of general rejuvenation, it is necessary to combine specific active principles for drug delivery. In this manner, it is possible to infer that the combined technique of microneedling and drug delivery for rejuvenating the skin of the anterior thorax region provided a significant improvement in the overall appearance, arising as a well tolerated procedure, with minimal adverse effects and high rates of patient satisfaction.

In addition, there is a scarcity of scientific studies published on this treatment modality, which strengthens the innovative and original character of the present study.
REFERENCES


